TEM: tempus.com P/E Multiple

Corporate emblem and logo of Tempus Labs (TEM)

Tempus AI, Inc (TEM) connects leading oncologists with AI developers to advance personalized medicine, monetizing unique clinical data archives through paid access for pharmaceutical behemoths. This P/E ratio chart visualizes market expectations for business scaling, where -78.00 reflects the current value of the metric. Rapid growth is supported by aggressive hiring of biomedical analysts and generous stock option programs.

Tempus AI (TEM) Price to Earnings Ratio: for the period 12/31/2024 - 11/10/2026

Comprehensive metric breakdowns and analytics for Tempus AI, Inc (TEM)

- stock price and consensus target price:
Quote Chart Tempus AI Inc|TEM - Consensus Target
- market capitalization information:
Market Capitalization Tempus AI|TEM - Total Company Value
- company book value details:
Net Assets per Share Tempus|TEM - Company Net Assets|Market Value to Book Value tempus.com|TEM - Company Total Assets
- company liabilities and liquidity data:
Total Debt to Capital Tempus AI, Inc|TEM - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient tempus.com|TEM - Company Total Debt|Debt to Net Assets Ratio Tempus AI|TEM - Company Long-Term Debts|Short-Term Debt Volume Tempus|Immediate Liquidity Ratio tempus.com
- earnings and market multiples details:
TEM - Net Profit|Future Profit Tempus AI, Inc|TEM - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Tempus AI, Inc.|TEM - PEG Multiple|Company Value to EBITDA Tempus AI|TEM - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Tempus|TEM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months tempus.com|TEM - Earnings per share growth in current year|Projected earnings per share growth rate for next year Tempus AI, Inc
General company analysis:Tempus AI - TEM
Core merchandise of tempus.com

The P/E ratio reflects the relationship between market capitalization and net income, determining the cost of one dollar of business earnings. High values signal inflated expectations, while low values indicate an undervalued asset. By analyzing a company's average P/E, an investor assesses whether the growth premium is justified. For Tempus AI, Inc (TEM), this metric confirms the market's willingness to pay for the expansion of AI diagnostics within oncology centers and the pharmaceutical sector.

Key competitors

qiagen.com - Market Cap to Net Income|Price to Earnings Ratio IONS (Ionis)|P/E Multiple Repligen Corp (RGEN)|Price to Earnings Ratio Avidity RNA|Business Payback Period CRISPR (CRSP)|WGS: Price to Earnings Ratio|Company Value to Net Income RARE (ultragenyx.com)|BEAM: P/E Multiple|Sarepta Therapeutics (SRPT) - P/E Multiple|TWST (Twist Bio) - P/E Multiple|10x (TXG) - Business Payback Period|Price to Earnings Ratio NTLA (Intellia Therapeutics)|STOK (stoketherapeutics.com) - Company Value to Net Income|P/E Multiple BLFS (BioLife Solutions)|Business Payback Period Wave Life Sciences Ltd (WVE)|MAZE - Price to Earnings Ratio|SION (Sionna Corp) - Price to Earnings Multiple|PRME: P/E Multiple|Price to Earnings Ratio tayshagtx.com|Price to Earnings Ratio QURE|MGTX (MeiraGTx Holdings) - Market Price to Net Income Ratio|P/E Multiple RGNX|SLDB - Market Cap to Earnings|Price to Earnings Ratio Ocugen, Inc. OCGN|PACB - Price to Earnings Ratio|Benitec Biopharma - P/E Multiple|DSGN (Design Therapeutics Inc) - Price to Earnings Multiple|Rocket Pharmaceuticals Inc (RCKT) - Price to Earnings Ratio|Price to Earnings Multiple FDMT|LXEO (Lexeo Therapeutics Inc.) - P/E Multiple|P/E Multiple Korro Bio, Inc|Price to Earnings Ratio EDIT (Editas Medicine)|Market Price to Net Income Ratio SLN|P/E Multiple PRQR (ProQR Therapeutics)|Codexis Inc (CDXS) - Market Cap to Earnings|SGMO - Price to Earnings Ratio|Nautilus Biotechnology (NAUT) - Price to Earnings Ratio|Metagenomi (MGX) - Price to Earnings Ratio|Market Cap to Net Income DTIL (precisionbiosciences.com)|Price to Earnings Ratio GBIO|P/E Multiple Boundless Bio Inc|Price to Earnings Ratio Exicure, Inc. (XCUR)|Business Payback Period imunon.com|Phio Pharmaceuticals Corp. - Price to Earnings Ratio|Company Value to Net Income MBIO|TransCode - P/E Multiple|BNGO - P/E Multiple|APDN: P/E Multiple|BLUE - Business Payback Period|Price to Earnings Ratio IPA|OMGA: Company Value to Net Income|P/E Multiple OMIC|Business Payback Period Regulus|Price to Earnings Ratio Syros Pharmaceuticals SYRS|TBIO: Price to Earnings Multiple|TRACON Pharmaceuticals, Inc. - P/E Multiple|Unity Biotechnology Inc. (UBX) - Price to Earnings Ratio